Daily Management Review

Pfizer Lowers Its Top Profit Margin Following The Third Quarter’s Earnings


11/04/2016


The “average analyst” forecast of Pfizer’s earnings were missed by one percent per share.



The largest manufacturer of drugs in the U.S., Pfizer Inc., issued its “quarterly adjusted profit” which just fell a little short on standing up to the estimates of the analysts, while four cents were shaved off by the company from its “2016 earnings forecast” following the decision of putting an end to the plans of developing “cholesterol-lowering treatment”.
 
Putting aside the “special items”, Pfizer’s third quarter’s earning equals to sixty one percent per share, whereby the estimates made by the “average analyst” was missed by one percent, reports “Thomson Reuters I/B/E/S”. Ibrance is a treatment for breast cancer developed by Pfizer which brought in sale’s revenue of “$550 million”. However, it missed the “$576 million” forecast of consensus which was compiled by “Evercore ISI”.
 
On the other hand, the pain drug, Lyrica, generated sales amount of “$1.05 billion”, which too failed to meet the expectation of “$1.28 billion”, whereas the sale of “Prevnar vaccine” over shot the forecast of “$1.48 billion” and brought in “$1.54 billion”. Furthermore, Pfizer reported that it will abandon the development of “bococizumab”, a drug for lowering cholesterol, reason being cited as an “evolving treatment landscape”.
 
As a result, Pfizer brought down the top earning forecast margin of 2016 to “$2.43”, while it maintained the “lower end at $2.38”. Moreover, the company increased its “revenue forecast” from “$51 billion” to “$52 billion”, yet retained the upper limit at “$53 billion”. According to Reuters:
“Bococizumab, which belongs to a pricey new class of medicines called PCSK9 inhibitors, was always going to be late to the party, since two rival drugs hit the market last summer - Praluent, co-developed by Regeneron (REGN.O) and Sanofi SA (SASY.PA) and Repatha from Amgen Inc (AMGN.O)”.
 
 
 
 
References:
http://www.reuters.com/







Science & Technology

With China Set To Dominate, 1 Billion Could Be Using 5G By 2023

Deutsche Telekom unveils next gen 5G mobile antennas in Europe

Diamonds are now the new gold

Expert Body Says Driving In A Driverless Car In An Inebriated Condition Or On Drugs Should Be Legalized

SEC’s EDGAR database vulnerable to cyber threats

Research Says The Risk Of Severe Turbulence On Planes Will Increase Due To Climate Change

Barclays and CLS Group aim to replace SWIFT with blockchain

Designing Of Cars Being Done With Hologram Goggles At Ford

The Already Surging Cyber Attacks Are Set To Rise Even Further, Says A Study

Chinese to equip smartphones with OLED displays

World Politics

World & Politics

Scholar Says Political Appointees Not As Important As Financial Ones In China For The Economy

An Expected Change In Brussels Could Be Crucial For The Euro Zone

Destroying People Who Wouldn't Help One Of His Bankrupt Businesses Was All Trump Talked About When He Met Him In 1990s: Branson

Russia Is Worried About America’s Unpredictability

No oil contracts with Iraqi Kurdistan: Iraq’s oil ministry

Donald Trump lost $ 600 million during his presidency

Britain puts its weight behind Europe in the battle between Boeing and Bombardier

EU hopes to keep the Iran nuclear deal afloat